March 8, 2018 / 9:21 PM / 2 months ago

BRIEF-Myokardia Announces Positive Results From Phase 2 Pioneer-Hcm Study Of Mavacamten

March 8 (Reuters) - Myokardia Inc:

* MYOKARDIA ANNOUNCES POSITIVE RESULTS FROM LOW-DOSE COHORT OF PHASE 2 PIONEER-HCM STUDY OF MAVACAMTEN IN SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY PATIENTS

* MYOKARDIA INC - STUDY MET PRIMARY ENDPOINT AND KEY SECONDARY ENDPOINTS WITH STATISTICAL SIGNIFICANCE

* MYOKARDIA INC - STUDY RESULTS INFORM PHASE 3 EXPLORER-HCM DOSING; FIRST PATIENT PLANNED FOR Q2 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below